Ritter Pharmaceuticals Appoints William Merino, Ph.D., to its Board of Directors
January 17 2017 - 8:00AM
Marketwired
Ritter Pharmaceuticals Appoints William Merino, Ph.D., to its
Board of Directors
LOS ANGELES, CA-(Marketwired - Jan 17, 2017) - Ritter
Pharmaceuticals, Inc. (NASDAQ: RTTR) ("Ritter Pharmaceuticals" or
the "Company"), a developer of novel therapeutic products that
modulate the human gut microbiome to treat gastrointestinal
diseases, today announced it has appointed William Merino, Ph.D.,
to its Board of Directors. Dr. Merino will occupy a newly-created
seat, advising on regulatory, clinical and related strategies.
Dr. Merino has over 30 years of global experience in drug and
device registration. He has worked extensively with senior members
of the U.S. Food and Drug Administration (FDA) as well as many
international regulatory authorities. Dr. Merino has previously
served as a Senior Clinical and Regulatory advisor to the Company
providing considerable guidance.
Ira E. Ritter, Chairman of the Board of Directors at Ritter
Pharmaceuticals stated, "Dr. Merino's deep regulatory experience
brings important insight and acumen having led the registration
process of many successful drugs, including the expedited
registration of the blockbuster drug, Lipitor. His long history of
success and leadership in the areas of regulatory affairs,
approvals and drug development will be invaluable as we interact
with the FDA and approach our ultimate goal of bringing RP-G28 to
market."
Dr. Merino added, "Ritter Pharmaceuticals is positioned to
potentially bring the first and only FDA approved treatment for
lactose intolerance to market. I am excited to join the company at
this time and look forward to making my contributions to this
strong team of board members."
Dr. Merino served as the Senior Vice President of Worldwide
Regulatory Affairs at Warner Lambert Pharmaceuticals, where he was
a member of the Office of the Chairman and responsible for the
registration and approval of pharmaceutical products with
regulatory agencies around the world. He was also responsible for
quality assurance, quality control and drug safety for the company.
While at Warner Lambert, Dr. Merino led efforts to gain expedited
registration of Lipitor in the United States and abroad in 20 other
countries. He also has previous experience leading international
regulatory affairs at Alcon Pharmaceuticals, G.D. Searle & Co.
and Riker Laboratories. Dr. Merino earned his Ph.D. in Pharmacology
from Purdue University.
About Ritter Pharmaceuticals
Ritter Pharmaceuticals, Inc. develops novel therapeutic products
that modulate the gut microbiome to treat gastrointestinal
diseases. Its lead product, RP-G28, has the potential to become the
first FDA-approved treatment for lactose intolerance, a condition
that affects millions worldwide. The company is further exploring
functionality and discovering therapeutic potential gut microbiome
changes may have on treating/preventing a variety of areas
including: gastrointestinal diseases, immune-oncology, metabolic,
and liver disease.
Forward-Looking Statements This release may contain
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995, including statements
related to our ability to bring RP-G28 to market. Management
believes that these forward-looking statements are reasonable as
and when made. However, such statements involve a number of known
and unknown risks and uncertainties that could cause the Company's
future results, performance or achievements to differ significantly
from the results, performance or achievements expressed or implied
by such forward-looking statements. These risks and uncertainties
include, but are not limited to, risks associated with the drug
development process generally, including the outcomes of planned
clinical trials and the regulatory review process. For a discussion
of certain risks and uncertainties affecting Ritter
Pharmaceuticals' forward-looking statements, please review the
Company's reports filed with the Securities and Exchange
Commission, including, but not limited to, its Annual Report on
Form 10-K for the period ended December 31, 2015 and its Quarterly
Reports on Form 10-Q for the periods ended March 31, 2016, June 30,
2016 and September 30, 2016. Readers are cautioned not to place
undue reliance on these forward-looking statements, which speak
only as of the date on which they are made. These statements are
based on management's current expectations and Ritter
Pharmaceuticals does not undertake any responsibility to revise or
update any forward-looking statements contained herein, except as
expressly required by law.
Company Contacts Ellen Mochizuki 310-203-1000
ellen@ritterpharma.com
Ritter Pharmaceuticals (NASDAQ:RTTR)
Historical Stock Chart
From Mar 2024 to Apr 2024
Ritter Pharmaceuticals (NASDAQ:RTTR)
Historical Stock Chart
From Apr 2023 to Apr 2024